Upcoming Webinar:Join our experts for discussion on ‘Re-inventing Finance: with Process, People & Technology’.
you are here: HomeNewsWorld

Sinopharm needs trial results to decide if COVID-19 shot needs booster: Executive

Antibodies triggered by two COVID-19 vaccine products from Sinopharm both have good neutralising effect on variants found in Britain and South Africa, Zhang told a news conference.

March 28, 2021 / 02:28 PM IST
Source: Reuters

Source: Reuters

China National Pharmaceutical Group (Sinopharm) will need to assess results from Phase III clinical trials to decide whether its two-shot COVID-19 vaccine should be followed by a booster shot, Zhang Yuntao, vice president at China National Biotec Group (CNBG), an affiliate of Sinopharm, said on Sunday.

Antibodies triggered by two COVID-19 vaccine products from Sinopharm both have good neutralising effect on variants found in Britain and South Africa, Zhang told a news conference.
Reuters
first published: Mar 28, 2021 01:40 pm
Sections